Sheng, X. et al. Disitamab vedotin plus toripalimab in HER2-expressing advanced urothelial cancer. N. Engl. J. Med. 393, 2324–2337 (2025).
Google Scholar
Raggi, D. et al. HER2 and urothelial carcinoma: current understanding and future directions. Nat. Rev. Urol. 23, 110–132 (2026).
Google Scholar
Hussain, M. H. A. et al. Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. J. Clin. Oncol. 25, 2218–2224 (2007).
Google Scholar
Wülfing, C. et al. A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma. Cancer 115, 2881–2890 (2009).
Google Scholar
Meric-Bernstam, F. et al. Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial. J. Clin. Oncol. 42, 47–58 (2024).
Google Scholar
Hashimoto, M. et al. Immunohistochemical analysis of HER2, EGFR, and Nectin-4 expression in upper urinary tract urothelial carcinoma. Anticancer Res. 43, 167–174 (2023).
Google Scholar
Banerji, U. et al. Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study. Lancet Oncol. 20, 1124–1135 (2019).
Google Scholar
Scherrer, E., Kang, A., Bloudek, L. M. & Koshkin, V. S. HER2 expression in urothelial carcinoma, a systematic literature review. Front. Oncol. 12, 1011885 (2022).
Google Scholar
Ye, J., Liao, X., Qiu, Y., Wei, Q. & Bao, Y. A systematic review and meta-analysis for human epidermal growth factor receptor 2 on upper tract urothelial carcinoma patients. Tumori 110, 25–33 (2024).
Google Scholar
Grigg, C. M. et al. Human epidermal growth factor receptor 2 overexpression is frequently discordant between primary and metastatic urothelial carcinoma and is associated with intratumoral human epidermal growth factor receptor 2 heterogeneity. Hum. Pathol. 107, 96–103 (2021).
Google Scholar
Sheng, X. et al. Efficacy and safety of disitamab vedotin in patients with human epidermal growth factor receptor 2-positive locally advanced or metastatic urothelial carcinoma: a combined analysis of two phase II clinical trials. J. Clin. Oncol. 42, 1391–1402 (2024).
Google Scholar
Gouda, M. A. et al. Human epidermal growth factor receptor 2 loss following treatment with trastuzumab deruxtecan in patients with metastatic breast cancer. Clin. Cancer Res. 31, 1268–1274 (2025).
Google Scholar
Taniguchi, H. et al. Tissue-agnostic efficacy of trastuzumab deruxtecan (T-DXd) in advanced solid tumors with HER2 amplification identified by plasma cell-free DNA (cfDNA) testing: results from a phase 2 basket trial (HERALD/EPOC1806). J. Clin. Oncol. 41, 3014 (2023).
Google Scholar
